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Molecular Mechanism for Changes in Proteoglycan Binding on
Compositional Changes of the Core and the Surface of
Low-Density Lipoprotein–Containing Human
Apolipoprotein B100
Christofer Flood, Maria Gustafsson, Robert E. Pitas, Lorenzo Arnaboldi,
Rosemary L. Walzem, Jan Bore´n
Objective—The aim of this study was to investigate the molecular mechanism for changes in proteoglycan binding and
LDL receptor affinity on two compositional changes in LDL that have been associated with atherosclerosis: cholesterol
enrichment of the core and modification by secretory group IIA phospholipase A2 (sPLA2) of the surface.
Methods and Results—Transgenic mice expressing recombinant apolipoprotein (apo) B and sPLA2 were generated.
Recombinant LDL were isolated and tested for their proteoglycan and LDL receptor-binding activity. The results show
site A (residues 3148-3158) in apoB100 becomes functional in sPLA2-modified LDL and that site A acts cooperatively
with site B (residues 3359-3369), the primary proteoglycan-binding site in native LDL, in the binding of sPLA2-
modified LDL to proteoglycans. Our results also show that cholesterol enrichment of LDL is associated with increased
affinity for proteoglycans and for the LDL receptor. This mechanism is likely mediated by a conformational change of
site B and is independent of site A in apoB100.
Conclusion—Site A in apoB100 becomes functional in sPLA2-modified LDL and acts cooperatively with site B resulting
in increased proteoglycan-binding activity. The increased binding for proteoglycans of cholesterol-enriched LDL is
solely dependent on site B. (Arterioscler Thromb Vasc Biol. 2004;24:564-570.)
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High levels of plasma low-density lipoproteins (LDL) area major risk factor for coronary disease and are the
source of most of the cholesterol that accumulates in the
arterial wall. Subendothelial retention of LDL is a key
pathogenic process in atherosclerosis,1,2 and several lines of
evidence suggest that intramural retention of atherogenic
lipoproteins involves the extracellular matrix, chiefly proteo-
glycans.1 Subsequently, a series of biological responses to
this retained material leads to an inflammatory response that
promotes lesion formation and increased retention of athero-
genic lipoproteins.1
Proteoglycans contain long carbohydrate side-chains of
glycosaminoglycans, which are covalently attached to a core
protein by a glycosidic linkage. The glycosaminoglycans
consist of repeating disaccharide units, all bearing negatively
charged groups, usually sulfate or carboxylic acid groups. In
vitro, LDL binds with high affinity to many proteoglycans
found in the artery wall. The interaction between LDL and
proteoglycans involves basic amino acids in apolipoprotein
(apo) B100, the protein moiety of LDL, that interact with the
negatively charged glycosaminoglycans3–5 or bridging mole-
cules such as apoE or lipoprotein lipase.1
Isolation of large fragments of apoB100 from different
regions characterized by concentrations of positive clusters
indicated that up to 8 specific regions in delipidated apoB100
bind proteoglycans.6–8 Two of these sites (site A at residues
3148 to 3158 and site B at residues 3359 to 3369) have been
proposed to act cooperatively in the association with proteo-
glycans.9 In the human sequence, a disulfide link between
Cys-3167 and Cys-3297 has been postulated to bring the two
sites into close proximity.6 However, these cysteine residues
are not conserved in other species.7 We have earlier shown
that LDL in which the basic amino acid residues of site B
have been mutated to neutral amino acid residues (RK3359-
3369SA LDL) fail to interact with proteoglycans.8 This result
indicates that site B is the primary proteoglycan-binding site
in apoB100 when the protein is associated with native LDL.8
However, the conformation of apoB100 on the surface of the
LDL particle is likely dependent on the composition of the
core lipids, the surface phospholipid content, and the diame-
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ter of the LDL particle. Thus, other binding sites may become
functional in modified LDL.
An elevated plasma level of secretory group II phospho-
lipase A2 (sPLA2) is a strong independent risk factor for
coronary heart disease.10 Whether this is associated with the
proatherogenic mechanisms of sPLA2 activity in plasma or
with its actions in the arterial wall remains to be elucidated.
In blood plasma, sPLA2 can modify the circulating lipopro-
teins, inducing the formation of small dense LDL particles,
which are associated with increased risk of cardiovascular
disease. Lipolysis of LDL by sPLA2 alters the expression of
apoB100 epitopes on the LDL particle,11 and sPLA2-modified
LDL display increased interaction with glycosaminogly-
cans.12 The plasma concentration of sPLA2 is increased in
systemic inflammations, such as rheumatoid arthritis (RA),13
which is known to be associated with increased risk of
coronary heart disease, and LDL from RA patients has
increased binding affinities to glycosaminoglycans.13
Willner et al recently showed that the enrichment of
cholesterol of LDL is another important risk factor for
atherosclerosis; triglyceride-rich apoB-containing lipopro-
teins are not as atherogenic as those containing cholesteryl
esters.14 The authors proposed that the inflammatory response
in atherosclerosis occurs primarily in response to toxicity
from cholesterol accumulation in lesions.14 However, it has
also been shown that the triglyceride content of LDL are
reciprocally related to the number of exposed free lysine
amino groups of apoB100.15 This could indicate that the
increased atherogenicity of cholesteryl ester-rich LDL could,
at least partly, be linked to an increased affinity for artery
wall proteoglycans.
In this study, we tested the hypothesis that site A is
important for proteoglycan-binding in sPLA2-modified LDL.
Here we show that site A acts cooperatively with site B to
increase the affinity of sPLA2-modified LDL for artery wall
proteoglycans. We also show that cholesterol enrichment of
the LDL particle is associated with increased affinity for
proteoglycans. This mechanism is likely mediated by a
conformational change of site B and is independent of site A.
Methods
Chemicals for SDS-PAGE were from Bio-Rad (Hercules, Calif). All
other chemicals were from Sigma (Stockholm, Sweden). Horseradish
peroxidase-conjugated polyclonal antibody against human apoB was
from the Binding Site (Birmingham, UK); 1-Step Turbo TMB-
ELISA was from Pierce (Rockford, Ill).
Generation of Transgenic Mice Expressing
RK3148-3158SQ ApoB100-Containing LDL
The 95-kb apoB P1 plasmid p15816 was prepared and modified by
RecA-assisted restriction endonuclease cleavage.17 See online Meth-
ods, available at http://atvb.ahajournals.org. The resulting P1 plas-
mid encodes RK3148-3158SQ apoB100 in which the basic residues
arginine and lysine in site A are replaced with serine and glutamine,
respectively. The plasmid also contains a CAA to CTA mutation in
codon 2153 that effectively abolishes the formation of apoB48 in
mouse livers.17 The structure of human apoB100 containing the
mutation is largely preserved when expressed in the mouse,18 and the
mutation does not affect proteoglycan binding or interaction with the
LDL receptor.7 P1 DNA was prepared and microinjected into
fertilized mouse eggs (FVB/N) and back-crossed into C57BL/6J
Bom. The two founders with the highest levels of plasma apoB were
selected for breeding and further analysis.
Isolation of LDL
LDL (density1.02 to 1.05 g/mL) were isolated from human
apoB100 transgenic expressing RK3148-3158SQ LDL, RK3359-
3369SA LDL19 or recombinant control LDL19 by sequential ultra-
centrifugation and dialyzed against 150 mmol/L NaCl and 0.01%
EDTA, with pH 7.4.19 Mouse apoE and apoB were removed by
immunoaffinity chromatography with rabbit polyclonal antibodies.19
Lion LDL was isolated identically19 from lion plasma pooled from 8
lions of different ages and sexes.
Competition of Mouse apoE With Chemically
Modified Human apoE
ApoB-containing lipoproteins (density1.02 to 1.05 g/mL) isolated
from transgenic LDL receptor-deficient (Ldlr/ or Ldlr/) mice
were incubated with a 200-fold molar excess of cyclohexanedione-
modified apoE from human very-LDL as described by Skåle´n et al.2
Characterization of Isolated Lipoproteins
The binding of LDL to biglycan or decorin was assessed with
solid-phase assays as described in detail by Skåle´n et al.2 Competi-
tive LDL receptor-binding assays were performed as described,19
and the amount of unlabeled lipoproteins needed to complete 50%
with iodine (I) 125-labeled LDL after a 3-hour incubation at 4°C was
determined from an exponential decay curve-fitting model.19 Li-
poprotein particle diameters were determined by dynamic light-
scattering analysis with a Microtrac Series 250 Ultrafine particle
analyzer fitted with a flexible conduit-sheathed probe tip (UPA-250;
Microtrac, Clearwater, Fla).21
Lipolysis of Recombinant and Lion LDL
With PLA2
LDL (1 mg/mL) was incubated for 3 hours in 100 mmol/L HEPES,
5 mmol/L CaCl2, 2 mmol/L MgCl2, 140 mmol/L NaCl, and
10 mol/L butylated hydroxytoluene, with pH 7.4, with or without
50 ng/mL PLA2 (from bee venom) in the presence of 2% (weight/
volume) bovine serum albumin.22 Lipolysis was stopped by adding
EDTA to achieve a final concentration of 10 mmol/L as described.22
Samples of the reaction were separated by fast performance liquid
chromatography gel filtration (KTA Explorer; Amersham Pharma-
cia) with a Superose 6 HR 10/30 column. Aliquots of 200 L were
injected onto the column and separated with PBS buffer, with pH
7.4, at a flow rate of 0.2 mL/min. The fractions corresponding to
non-aggregated LDL were subjected to binding studies.
Data Analysis
Curve-fit analysis was performed in GraphPad Prism version 3.00
for Windows using a nonlinear curve-fit assuming one-site binding
(San Diego, Calif). Statistical analysis was performed using SigmaS-
tat for Windows version 2.03 (SPSS, Chicago, Ill).
Results
Generation and Characterization of Recombinant
RK3148–3158SQ LDL
To evaluate the importance of site A (residues 3148-3158) in
the interaction between native apoB100-containing LDL and
proteoglycans, we generated transgenic mice expressing hu-
man recombinant LDL in which site A in apoB100 was
mutated by substituting serines and glutamines for arginines
and lysines, respectively (RK3148-3158SQ). Recombinant
control LDL, RK3148-3158SQ LDL, and RK3359-3369SA
LDL19 were isolated from mouse plasma by ultracentrifuga-
tion, and lipoproteins containing endogenous mouse apoE
and apoB were removed by immunoaffinity chromatography;
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the removal of all endogenous apoB and apoE was confirmed
by Western blot analysis (not shown). In RK3359-3369SA
LDL, the arginine residues were converted to serines and the
lysine residues were changed to alanines in site B of
apoB100.19 Previously, we showed that site B (residues
3359-3369) is the combined proteoglycan binding and LDL
receptor binding site in apoB100 and that RK3359-3369SA
LDL do not interact with proteoglycans or the LDL receptor.7
The isolated recombinant control LDL, RK3148-3158SQ
LDL, and RK3359-3369SA LDL had almost identical lipid
compositions (data not shown) and particle diameters
(27.10.86, 26.70.20, and 26.80.85 nm, respectively;
meanSD).
To determine the ability of the recombinant LDL to
interact with proteoglycans, we subjected recombinant con-
trol LDL, RK3148-3158SQ LDL, and RK3359-3369SA LDL
to solid-phase assays with biglycan (Figure 1A) and decorin
(not shown). In two independent experiments, recombinant
control LDL and recombinant RK3148-3158SQ LDL bound
biglycan with high affinity, whereas recombinant RK3359-
369SA LDL displayed severely impaired binding (Figure 1A).
To investigate the importance of site A in the interaction
with the LDL receptor, we isolated recombinant control LDL,
RK3148-3158SQ LDL, and RK3359-3369SA LDL and
tested them in an in vitro competitive receptor-binding assay
(Figure 1B). Recombinant control LDL and RK3148-3158SQ
LDL had almost identical receptor binding (ED50 2.1 and 2.3
g/mL, respectively), whereas recombinant RK3359-
3369SA LDL displayed defective receptor binding (ED50
20 g/mL). Taken together, these results indicate that site
A in native LDL is not involved in binding to proteoglycans
or to the LDL receptor.
Solid-Phase Assays of Recombinant LDL Isolated
From sPLA2 Transgenic Mice
Next, we tested the hypothesis that site A can modulate the
proteoglycan binding activity of modified LDL. Recombinant
control LDL, RK3148-3158SQ LDL, and RK3359-3369SA
LDL were isolated by ultracentrifugation from human apoB
transgenic mice and from doubly transgenic mice expressing
human apoB and sPLA2.23 After removal of endogenous
mouse apoE-containing and apoB-containing lipoproteins by
immunoaffinity chromatography, the isolated recombinant
LDL were subjected to solid-phase assays with biglycan
(Figure 2A) and decorin (not shown). In two independent
experiments, recombinant control LDL from sPLA2 trans-
genic mice displayed increased binding, whereas recombinant
RK3148-3158SQ LDL from sPLA2 transgenic mice and
sPLA2 nontransgenic littermate controls had almost identical
binding (Figure 2A). These results indicate that site A is
important for the increased interaction of sPLA2-modified
LDL with glycosaminoglycans. However, RK3359-3369SA
LDL did not interact with biglycan, regardless of whether it
was isolated from sPLA2 transgenic mice or not (Figure 2B).
These results indicate that site A in sPLA2-modified LDL
modulates the binding of the LDL particle to proteoglycans
but cannot substitute for site B, which is essential for the
interaction with proteoglycans.
Characterization of sPLA2-Modified
Recombinant LDL
sPLA2 hydrolyzes glyceroacyl phospholipids to form nones-
terified fatty acids and lysophospholipids. Therefore, we
analyzed the phospholipid composition of recombinant LDL
isolated from human apoB transgenic mice and from apoB
transgenic mice with mice expressing sPLA2 (apoBsPLA2
Figure 1. Solid-phase assays of the binding of LDL to biglycan
(A) and competitive receptor binding assay of recombinant LDL
(B). The abilities of recombinant control LDL (), RK3148-
3158SQ LDL (f), and RK3359-3369SA LDL (Œ) to bind biglycan
or compete with 125I-labeled human plasma LDL (2 g/mL) for
binding to LDL receptors on normal human fibroblasts were
determined. The recombinant lipoproteins were isolated from 20
mice, and endogenous apoE and apoB were removed by affinity
chromatography. The results represent mean values (SD) from
2 independent experiments, each performed with freshly iso-
lated LDL (n4 in each experiment) (A) or the mean of 2 inde-
pendent experiments, each performed in duplicate (B).
Figure 2. Binding of recombinant LDL isolated from sPLA2
transgenic mice to biglycan. The abilities of recombinant control
LDL () and RK3148-3158SQ LDL (f) and RK3359-3369SA LDL
(Œ) isolated from human apoB transgenic mice (, f, Œ) and
from apoBsPLA2 transgenic mice (, ‚, ) to bind biglycan
were determined. Endogenous mouse apoB and apoE were
removed from all lipoproteins by immunoaffinity chromatogra-
phy. The results represent mean values (SD) from two inde-
pendent experiments, each performed with freshly isolated LDL
from 15 mice of each group (n4 in each experiment).
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transgenic mice). The sPLA2-modifed LDL contained more
lysophosphatidylcholine than nonmodified recombinant LDL
(Table 1). We also analyzed the content of total cholesterol,
free cholesterol, cholesteryl esters, and triglycerides. No
differences were found in the content of these lipids in
recombinant LDL isolated from apoB transgenic mice or
from apoBsPLA2 transgenic mice (Table 2). Neither the
phospholipid composition (Table 1) nor the content of the
other lipids (Table 2) was affected by the type of apoB100
(control or the two mutations, ie, RK3148-3158SQ or
RK3359-3369SA) in LDL isolated from apoB transgenic
mice or from apoBsPLA2 transgenic mice (data not shown).
Dynamic light-scattering analysis of recombinant control
LDL isolated from human apoB transgenic mice and from
apoBsPLA2 transgenic mice showed that recombinant LDL
from the singly human apoB transgenic mice was signifi-
cantly larger (26.70.42 versus 25.80.38 nm;, mean SD;
P0.05). Taken together, these results show that in vivo
modification of recombinant LDL in sPLA2 transgenic mice
induces the formation of smaller LDL enriched in lysophos-
phatidylcholine. Thus, it is possible that the conformational
change of apoB in LDL modified with sPLA2 in vivo is
caused by the formation of smaller LDL and/or by changes in
the phospholipids composition of the LDL particle.
Solid-Phase Assays of Recombinant LDL Isolated
From sPLA2 Transgenic Mice by
Size-Exclusion Chromatography
To discriminate between these possibilities, recombinant
control LDL and RK3148-3158SQ LDL were isolated from
human apoB transgenic mice and from apoBsPLA2 trans-
genic mice by a combination of ultracentrifugation and
size-exclusion chromatography and subjected to solid-phase
assays with biglycan. The isolated LDL had almost identical
size (26.40.23 and 26.30.15 nm). In two independent
experiments, recombinant control LDL from sPLA2 trans-
genic mice displayed increased binding, whereas recombinant
RK3148-3158SQ LDL from sPLA2 transgenic mice and
sPLA2 nontransgenic littermate controls had almost identical
binding. The Kd for control LDL and RK3148-3158SQ LDL
isolated from apoB transgenic mice were 16.3 and 17.1,
respectively, and from apoBsPLA2 transgenic mice 10.3
and 16.6, respectively. The results also showed that the
diameter of sPLA2-modified and non-modified recombinant
control LDL were inversely correlated to the binding affinity
to biglycan; smaller LDL had higher binding affinity to
biglycan than larger LDL (data not shown). Taken together,
the results show that the conformational change of apoB in
sPLA2-modified LDL is caused by the formation of smaller
LDL and by changes in the phospholipid composition of the
LDL particle.
To investigate if in vitro digestion and in vivo modification
of LDL with PLA2 give similar results, recombinant control
LDL, RK3359-3369SA LDL, and RK3148-3158SQ LDL
were isolated and digested in vitro with PLA2 for 3 hours.
Samples of the reaction were separated by size-exclusion
chromatography, and non-aggregated LDL was isolated and
subjected to binding studies. This was performed because
lipolysis of LDL with PLA2 in vitro induces particle aggre-
gation.22 The results from these studies showed that in vitro
modification of recombinant LDL with PLA2 gave similar
results as in vivo modification of LDL, ie, binding affinity
increased on PLA2 digestion and site A was required for the
increased interaction of sPLA2-modified LDL with glycos-
aminoglycans (data not shown). However, the intra-assay
variations (ie, imprecision) and the inter-assay variations (ie,
irreproducibility) were much more pronounced when analyz-
ing the binding of LDL digested with PLA2 in vitro compared
with LDL modified in vivo.
Binding of Lion LDL to Biglycan and to the
LDL Receptor
Our data indicate that site A becomes exposed and functional
on sPLA2 modification and that site A and site B act
cooperatively in binding to proteoglycans. In the human
sequence, site A and site B are separated by 202 amino acids,
but a disulfide link between Cys-3167 and Cys-3297 has been
postulated to bring the two binding sites into close proximi-
ty.10 However, these cysteine residues are not conserved in
other species;6 but because of a naturally occurring deletion
between site A and site B in several carnivores, including
lions, the binding sites are separated by 76 amino acids only
in these species.24 Therefore, we investigated the
proteoglycan-binding activity of lion LDL with and without
PLA2 digestion.
Lion LDL and human LDL were isolated and digested in
vitro with PLA2 for 3 hours and non-aggregated LDL was
isolated by a combination of ultracentrifugation and size-
exclusion chromatography. The PLA2 modification induced
TABLE 1. Phospholipid Composition of Recombinant LDL
Isolated From Human apoB Transgenic Mice and From
Double-Transgenic apoBsPLA2 Mice
Human Recombinant
LDL
sPLA2-Modified
LDL
Lysophosphatidylcholine 7.431.4* 10.031.03*
Sphingomyelin 7.770.91 8.770.74
Phosphatidylcholine 79.83.41 77.170.21
Phosphatidylinositol 4.11.4 3.430.38
Phosphatidylethanolamine 0.871.5 0.570.98
Total phosphorus (nmol/g protein) 1.830.024 1.680.023
Values are meanSD of % phosphorous content (nmol) of three different
experiments.
Comparisons between independent groups were performed with Mann–
Whitney U test.
*Significant change; P0.05.
TABLE 2. Lipid Composition of Recombinant LDL Isolated
From Human apoB Transgenic Mice and From
Double-Transgenic apoBsPLA2 Mice
Human Recombinant
LDL
sPLA2-Modified
LDL
Total cholesterol 1.580.06 1.510.06
Free cholesterol 0.610.02 0.580.03
Triglycerides 1.320.11 1.240.07
Cholesteryl esters 0.970.04 0.930.03
Phospholipids 0.046 0.042
Results represent mean values (SD) (n5) in g lipid/g protein.
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the formation of smaller LDL enriched in lysophosphatidyl-
choline. The diameter of lion LDL and human LDL decreased
from 27.20.33 to 26.10.25 nm and from 27.50.39 to
26.30.15 nm, respectively. The content of lysophosphati-
dylcholine in PLA2-digested LDL increased 2.4-fold0.3 and
2.8-fold0.6, respectively.
As shown by SDS-PAGE, lion apoB migrated faster than
human apoB100, and the LDL did not contain any apoli-
poprotein other than apoB (Figure 3A). In solid-phase assays,
lion LDL bound with higher affinity than human LDL to
biglycan; however, PLA2 modification did not increase the
binding of lion LDL to biglycan, as was seen in human LDL
(Figure 4A). The Kd for lion and human LDL were 10.2 and
15.4, respectively, and for PLA2-modified lion and human
LDL 10.4 and 11.3, respectively. The binding capacity of lion
and human LDL was similar (Bmax 0.71 and 0.66, respec-
tively), indicating that the deletion between sites A and B
increases the affinity for proteoglycans but not the binding
capacity. In competitive LDL receptor-binding studies with
human 125I-labeled LDL, lion and human LDL had almost
identical receptor binding (ED50 1.9 and 1.8 g/mL, respec-
tively). These results are consistent with the hypothesis that
site A is functional on lion LDL with or without PLA2
modification.
Solid-Phase Assays of Cholesterol-Enriched
ApoB100 Recombinant LDL With Biglycan
To analyze if cholesterol enrichment of LDL is associated
with increased affinity for proteoglycans, human apoB trans-
genic mice expressing recombinant control LDL, RK3148-
3158SQ LDL, or RK3359-3369SA LDL were bred onto
Ldlr/ background. Recombinant LDL isolated from Ldlr/
mice is enriched with cholesteryl esters. The total cholesterol
to triglyceride (in mmol/L) ratios in recombinant LDL iso-
lated from human apoBLdlr/ transgenic mice and
apoBLdlr/ transgenic mice are 1.7 and 4.2, respectively.
Recombinant control LDL and RK3148-3158SQ LDL
from Ldlr/ and Ldlr/ mice were isolated by ultracentrif-
ugation, and endogenous mouse apoB and apoE were re-
moved. LDL isolated from Ldlr/ mice is greatly enriched in
endogenous apoE (Figure 3B), and immunoaffinity tech-
niques fail to remove all endogenous apoE from LDL isolated
from Ldlr/ mice.1,2 Competition of mouse apoE with
CHD-modified human apoE efficiently removes the endoge-
Figure 3. Coomassie staining and Western analysis of apoB-
containing LDL. A, Lion and human plasma LDL (density1.02
to 1.05 g/mL) were isolated by sequential ultracentrifugation.
Five micrograms of LDL were separated by SDS-PAGE with 3%
to 15% gels. Arrows indicate molecular mass markers. B,
Recombinant LDL (density1.02 to 1.05 g/mL) was isolated
from LDLR/ mice (HuApoBLDLR/) or LDLR/ mice (HuA-
poB), and 2 g were analyzed on SDS-PAGE with 3% to 15%
gels. C, Endogenous apoB was removed by immunoaffinity
chromatography, and 0.5 g of recombinant control LDL (densi-
ty1.02 to 1.05 g/mL) from LDLR/ mice (lane 1) or LDLR/
mice (lane 2) was analyzed by Western blots with polyclonal
antibodies against mouse apoE. Lane 3 shows recombinant
control LDL (0.5 g) from LDLR/ mice analyzed by Western
blots with polyclonal antibodies against mouse apoE (upper
panel) and human apoE (lower panel) after incubation with CHD-
modified human apoE (HuApoE competition). The CHD-modified
samples were incubated with an equal volume of 1 mol/L
hydroxylamine, 0.3 mol/L mannitol, at pH 7.0, at 37°C for 16
hours to reverse the modification of the arginine residues before
sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Figure 4. Solid-phase assays of lion LDL or recombinant LDL
isolated from Ldlr/ and Ldlr/ mice to biglycan binding to
biglycan. A, Lion (f) and human () plasma LDL (density1.02
to 1.05 g/mL) were isolated by sequential ultracentrifugation and
incubated with ( and ) or without ( and f) 50 ng/mL of
PLA2 (from bee venom). To prevent overlap in the figure, f and
 have been moved by 0.5 and 0.5 U on the X-axis,
respectively. B, The abilities of recombinant control LDL () and
RK3148-3158SQ LDL (f) isolated from Ldlr/ ( and ) and
Ldlr/ ( and f) mice to biglycan were determined. Endoge-
nous apoE was replaced with cyclohexanedione-modified
human apoE, and endogenous mouse apoB was removed by
immunoaffinity chromatography. The results represent mean val-
ues (SD) from two independent experiments, each performed
with freshly isolated LDL from 15 mice of each group (n4 in
each experiment).
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nous apoE from the recombinant LDL (Figure 3C), and the
CHD-modified apoE fail to facilitate an indirect binding
between the recombinant LDL and glycosaminoglycans.1,2
The competition of mouse apoE with chemically modified
human apoE did not affect the cholesterol or triglyceride
content of the LDL particles. The recovery of these lipids
were 94%8% and 92%11% after competition with CHD-
modified apoE, respectively (meanSD, n5).
The purified recombinant control LDL and RK3148-
3158SQ LDL from Ldlr/ and Ldlr/ mice were then
subjected to size-exclusion chromatography to isolate LDL
particles with almost identical size (diameters: 26.80.84
and 26.70.21 nm versus 26.91.87 and 26.80.42 nm,
respectively; meanSD). In two independent experiments,
recombinant control LDL and RK3148-3158SQ LDL isolated
from Ldlr-/- mice bound biglycan and decorin (not shown)
with higher affinity than recombinant control LDL and
RK3148-3158SQ LDL isolated from Ldlr/ mice (Figure
4B). Within each genotype, recombinant control LDL and
RK3148-3158SQ LDL displayed almost identical binding.
The Kd for control LDL and RK3148-3158SQ LDL isolated
from Ldlr/ were 17.0 and 16.7, respectively, and from
Ldlr/ mice 9.1 and 8.2, respectively. The binding capacity
of recombinant control LDL and RK3148-3158SQ LDL was
almost identical, both when isolated from Ldlr/ and from
Ldlr/ mice (Bmax were 0.51, 0.47, 0.51, and 0.48, respec-
tively). Control experiments showed that RK3359-3369SA
LDL from both Ldlr/ and Ldlr-/- mice had severely impaired
binding (data not shown). Competitive receptor-binding stud-
ies with human 125I-labeled LDL showed that cholesterol-
enriched recombinant control LDL from Ldlr/ mice bound
with higher affinity to the LDL receptor than that from
Ldlr/ mice (ED50 1.7 versus 2.5 g/mL).
These findings indicate that cholesterol enrichment of the
LDL particle is associated with increased affinity for proteo-
glycans and for the LDL receptor. This mechanism is likely
mediated by a conformational change of site B and is
independent of site A in apoB100.
Discussion
The aim of this study was to investigate the molecular
mechanism for changes in proteoglycan binding and LDL
receptor affinity on two compositional changes in LDL:
modification by secretory group IIA phospholipase A2
(sPLA2) of the surface and cholesterol-enrichment of the core.
Elevated plasma sPLA2 activity has been shown to be an
important risk factor for coronary heart disease.8 Thus, clarifi-
cation of the proatherogenic mechanisms by which sPLA2 acts in
the plasma and in the artery wall is important to our understand-
ing of the pathogenesis of the disease. To investigate the
molecular mechanism for how circulating sPLA2 induces the
increased binding affinities of LDL to glycosaminoglycans,13 we
crossed our human apoB transgenic mice with mice expressing
sPLA2.23 The serum activity of sPLA2 in these transgenic mice is
elevated approximately 8-fold compared with nontransgenic
littermates, but there is no evidence of systemic inflammation in
the transgenic mice.23 Here we show that in vivo modification of
recombinant LDL in sPLA2 transgenic mice induces the forma-
tion of slightly smaller LDL enriched with lysophosphatidylcho-
line. These results are in agreement with data of Grass et al23 and
with results from patients with rheumatoid arthritis who have
increased plasma levels of sPLA2.13 Taken together, our results
are consistent with the hypothesis that sPLA2 modification of
LDL in the circulation leads to exposure of site A, resulting in
increased proteoglycan binding. Furthermore, the conforma-
tional change of apoB in sPLA2-modified LDL is caused by the
formation of smaller LDL and by changes in the phospholipid
composition of the LDL particle.
However, it is conceivable that some of the observed effects
could result from indirect secondary consequences. For example,
sPLA2 modification might cause LDL with low PG binding to be
cleared, leaving behind a high-affinity subpopulation. It is also
possible that sPLA2 digestion in vivo allows a second enzyme to
further alter the LDL, eg, sphingomyelinase, which has been
reported to readily digest sPLA2-treated LDL.25 However, be-
cause a gentle PLA2 digestion of recombinant LDL in vitro gives
similar results, and because isolated LDL from apoBsPLA2
transgenic mice contain abundant sphingomyelin, these alterna-
tive explanations seems unlikely.
In some experiments, LDL was digested with PLA2 in vitro.
These incubations were performed for 3 hours only. The reason
for this was to achieve similar modification of LDL as in patients
with increased plasma levels of sPLA2.13 Prolonged digestion of
LDL with PLA2 in vitro results in hydrolysis of nearly all of the
phosphatidylcholines, in pronounced aggregation, and in the
presence of glycosaminoglycans fusion of LDL,22 ie, the mod-
ifications of LDL that are more likely to occur within the
extracellular matrix of the arterial wall.
The findings that lion LDL, with a 126-amino acid residue
deletion between site A and site B, has increased affinity for
artery wall proteoglycans and that PLA2 modification of lion
LDL did not increase the binding of lion LDL to biglycan are
consistent with the hypothesis that site A on lion LDL is also
exposed with or without sPLA2 modification. However, studies
with cross-linking or some other direct proof would be needed to
draw this conclusion. It is also possible that other basic se-
quences or even other apolipoproteins might play a role in the
unusual properties of lion LDL. However, the latter possibility
seems unlikely because no apolipoproteins other than apoB was
detected in isolated lion LDL (Figure 3A). The fact that two
independent deletions have been found in apoB100 between site
A and site B might indicate that these mutations provide an
evolutionary advantage. In addition to the 126-amino acid
deletion in several carnivores, including lions,24 an 84-amino
acid deletion has been found in elephants.24 A tentative hypoth-
esis is that an enhanced binding of LDL to matrix might promote
wound healing, as has been proposed, although not proven, for
Lp(a).26
Our results show that cholesterol-enriched LDL has increased
affinity for glycosaminoglycans and the LDL receptor. This
mechanism is likely mediated by a conformational change of site
B and is, in contrast to sPLA2-modified LDL, independent of site
A. The finding that cholesterol-enriched LDL have increased
affinity for artery wall proteoglycans offers an additional expla-
nation for why the atherogenicity of apoB-containing lipopro-
teins correlates with their cholesteryl ester content.
The binding studies with LDL isolated from Ldlr/ and
Ldlr/ mice were performed with LDL of almost identical
Flood et al Modulation of the Proteoglycan Binding of LDL 569
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diameters, and the results are consistent with the triglyceride-
dependent decrease in affinity for the LDL receptor reported in
hypertriglyceridemic subjects.27 However, our results are not
consistent with the finding that in the absence of changes in the
size of the particle, the relative content of neutral lipid in the core
of LDL does not significantly affect apoB conformation or its
affinity for the LDL receptor.28 The reasons for these differences
are unclear but could reflect differences in experimental design,
because the secondary structure of apoB in LDL strongly
depends on the physical state of the lipoprotein core.29
In this study, we tested the hypothesis that site A is important
for proteoglycan binding of sPLA2-modified LDL. The results
confirm that site B is the principal proteoglycan-binding site in
native apoB100-containing LDL and show that site A acts
cooperatively with site B in the association with proteoglycans
in sPLA2-modified LDL. The results also show that cholesterol
enrichment of the LDL particle is associated with increased
affinity for proteoglycans and for the LDL receptor. This
mechanism is likely mediated by a conformational change of site
B and is independent of site A in apoB100. Taken together, the
results show that LDL affinity for proteoglycans can be modified
by size-dependent effects and size-independent compositional
effects of either the surface or the core.
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Generation of a P1 Plasmid Encoding RK3148-3158SQ apoB100—The 95-kb apoB P1 plasmid 
6-GSBM (i.e. glycosaminoglycan-binding sites mutated)1 was prepared and modified by RecA-
assisted restriction endonuclease cleavage as described.2-4 The P1 plasmid 6-GBSM encodes 
human apoB100 with mutations in the six carboxyl-terminal glycosaminoglycan-binding 
sequences in delipidated apoB100.1 A 2.64-kb genomic DNA fragment containing the RK3148-
3158SQ mutation was isolated from the P1 plasmid with oligomers EcoRI-38863 and EcoRI-
41496 3, 4 and ligated into a pBluescript vector containing a 3.1-kb genomic apoB fragment 
(EcoRI-35763 to EcoRI-38863) along with the chloramphenicol-resistance/sacB selectable 
markers.5 The 5.7-kb apoB fragment together with the Cm/SacB sequence was isolated by 
RecA-assisted restriction endonuclease cleavage using the oligos 5′-
gcatattttaaacacaagtgaaatatctggttaggatagaattctcccagttttcacaatgaaaacatc-3′ and 5′-
gggaaaactcccacagcaagctaatgattatctgaattctcatgtttgacagcttatcatcg-3′ and ligated to a 5.7-kb-
deleted “B100 Leu-Leu” P1 vector plasmid 3. Plasmids containing the mutated apoB fragment 
and the chloramphenicol resistance/sacB genes were selected on chloramphenicol-containing 
plates.5 A P1 plasmid was then isolated and characterized by restriction enzyme digestion. The 
chloramphenicol resistance/sacB genes were removed with selection on 5% sucrose, leaving the 
mutated 5.7-kb fragment within the apoB gene. The resulting P1 plasmid encodes RK3148-
3158SQ apoB100 in which the basic residues arginine and lysine in Site A are replaced with 
glutamine and serine, respectively.  
LDL lipid analysis—Total cholesterol and triglyceride concentrations were determined by 
enzymatic assays from Roche Diagnostic (Mannheim, Germany), whereas free cholesterol was 
estimated using a cholesterol oxidase kit from Wako Chemicals (Neuss, Germany). For 
phospholipid analysis, lipids from LDL were extracted with chloroform/methanol (2:1). For 
 by on April 22, 2011 atvb.ahajournals.orgDownloaded from 
2 
each sample, four aliquots of extract were loaded on a multi channel (Baker Si-250) thin layer 
chromatography (TLC) plate. Phospholipids were separated in one dimension and their relative 
amount was quantitated by phosphorus assay in the presence of the silica gel.6 Background 
phosphorus was assayed in an adjacent lane on the TLC plate and subtracted from each value. 
Protein concentrations were determined with the Lowry assay.7  
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